EHA CAR-T Program
Available on the EHA Campus, the EHA CAR-T program is an eight-course program covering all aspects of CAR-T; mechanisms of action, the process of CAR-T manufacture and infusion, treatment of hematopoietic malignancies and patient selection, CRS, and other complications as well as ethics and consent, multidisciplinary care and regulatory aspects.
The courses in this program include interactive quizzes, links to video clips of experts, and suggestions for additional reading. This program has been peer-reviewed by Professor Hermann Einsele, Professor Maria Victoria Mateos, Professor Ulrich Jäger, Dr. Julio Delgado, and Dr. Inam Shafqat.
Current courses in the program include:
- Introduction to chimeric antigen receptor T-cell (CAR-T) therapy
- Processes in CAR-T
- Cytokine Release Syndrome (CRS) in CAR-T: From diagnosis to management
- Complications of CAR-T: Beyond CRS
- CAR-T therapy for hematopoietic malignancies
These additional courses will become available over the next few months.
- Ethics and consent in CAR-T
- Regulatory aspects of CAR-T
- What to expect in CAR-T
After completing this program, participants will be able to:
Understand the principles, mechanism of action, and toxicities associated with CAR-T therapy
Analyze the needs of hematology oncology in relation to CAR-T therapy within evidence-based practice
Integrate clinical guidelines, protocols and evidence-based practice related to CAR-T treatment of hematology patients
Develop holistic care packages and treatment pathways for patients requiring CAR-T therapy, including post-discharge planning
This program will become part of the EHA Immunotherapy program currently in development.